Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
30 October 2013Website:
http://www.veracyte.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 19:28:23 GMTDividend
Analysts recommendations
Institutional Ownership
VCYT Latest News
Invest in companies like Veracyte (VCYT), Steelcase (SCS) and Applied Industrial Technologies (AIT), as they boast higher efficiency levels.
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
The average of price targets set by Wall Street analysts indicates a potential upside of 39.1% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Invest in companies like Veracyte (VCYT), Signet Jewelers (SIG), UMB Financial (UMBF) and NVIDIA (NVDA) to make the most of higher efficiency levels.
Veracyte's (VCYT) new studies leverage Afirma GRID's whole-transcriptome approach to uncover novel molecular signatures and alterations.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer.
Veracyte, Inc. (Nasdaq: VCYT), a prominent cancer diagnostics company, has revealed its plans to attend upcoming investor conferences. These include the Leerink Partners 2024 Healthcare Crossroads Conference in Austin, TX, where they will participate in a Fireside Chat on May 29th at 12:20 p.m. Eastern Time, as well as the William Blair 44th Annual Growth Stock Conference in Chicago, IL, where they will give a presentation on June 4th at 5:40 p.m. Eastern Time. Live audio webcasts of the company's presentations will be accessible for viewing.
Analysts' average price targets for Veracyte (VCYT) suggest a potential 39.6% increase in the stock. Although this widely followed metric has not always been reliable, the consensus among analysts in increasing earnings estimates does hint at an upside for the stock.
Veracyte's (VCYT) fourth-quarter 2023 performance reflects solid financial discipline and the strength of the Decipher Prostate and Afirma tests.
Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Conference Call February 22, 2024 4:30 PM ET
What type of business is Veracyte?
Veracyte, Inc. is a leading company in the field of genomic diagnostics in the USA and abroad. The company was previously known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was registered in 2006, with headquarters located in South San Francisco, California. Veracyte, Inc. conducts a series of genomic tests for the detection of cancer and idiopathic pulmonary fibrosis in a CLIA-certified laboratory. The company uses advanced scientific methods such as whole transcriptome RNA sequencing and machine learning to develop tests and optimize analysis results.
What sector is Veracyte in?
Veracyte is in the Healthcare sector
What industry is Veracyte in?
Veracyte is in the Diagnostics & Research industry
What country is Veracyte from?
Veracyte is headquartered in United States
When did Veracyte go public?
Veracyte initial public offering (IPO) was on 30 October 2013
What is Veracyte website?
https://www.veracyte.com
Is Veracyte in the S&P 500?
No, Veracyte is not included in the S&P 500 index
Is Veracyte in the NASDAQ 100?
No, Veracyte is not included in the NASDAQ 100 index
Is Veracyte in the Dow Jones?
No, Veracyte is not included in the Dow Jones index
When does Veracyte report earnings?
The next expected earnings date for Veracyte is 08 August 2024